Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
Public ClinicalTrials.gov record NCT00162253. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical research study is to learn if BMS-587101 is effective on the treatment of Moderate to Severe Psoriasis. The safety of this treatment will also be studied.
Study identification
- NCT ID
- NCT00162253
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2005 (Type not available)
- Primary completion
- Jun 2006 (Actual)
- Completion
- Not listed
- Last update posted
- Mar 2, 2010
Started 2005
United States locations
- U.S. sites
- 16
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Phoenix | Arizona | — | — |
| Local Institution | Tucson | Arizona | — | — |
| Local Institution | San Diego | California | — | — |
| Local Institution | Miami Beach | Florida | — | — |
| Local Institution | Pinellas Park | Florida | — | — |
| Local Institution | Boise | Idaho | — | — |
| Local Institution | Fridley | Minnesota | — | — |
| Local Institution | St Louis | Missouri | — | — |
| Local Institution | New Brunswick | New Jersey | — | — |
| Local Institution | New York | New York | — | — |
| Local Institution | Winston-Salem | North Carolina | — | — |
| Local Institution | Columbus | Ohio | — | — |
| Local Institution | Portland | Oregon | — | — |
| Local Institution | Philadelphia | Pennsylvania | — | — |
| Local Institution | Greer | South Carolina | — | — |
| Local Institution | Dallas | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00162253, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 2, 2010 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00162253 live on ClinicalTrials.gov.